Literature DB >> 11914348

Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I.

Helena I Boshoff1, Valerie Mizrahi, Clifton E Barry.   

Abstract

The effects of low extracellular pH and intracellular accumulation of weak organic acids were compared with respect to fatty acid synthesis by whole cells of Mycobacterium tuberculosis and Mycobacterium smegmatis. The profile of fatty acids synthesized during exposure to benzoic, nicotinic, or pyrazinoic acids, as well as that observed during intracellular hydrolysis of the corresponding amides, was not a direct consequence of modulation of fatty acid synthesis by these compounds but reflected the response to inorganic acid stress. Analysis of fatty acid synthesis in crude mycobacterial cell extracts demonstrated that pyrazinoic acid failed to directly modulate the fatty acid synthase activity catalyzed by fatty acid synthase I (FAS-I). However, fatty acid synthesis was irreversibly inhibited by 5-chloro-pyrazinamide in a time-dependent fashion. Moreover, we demonstrate that pyrazinoic acid does not inhibit purified mycobacterial FAS-I, suggesting that this enzyme is not the immediate target of pyrazinamide.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11914348      PMCID: PMC134955          DOI: 10.1128/JB.184.8.2167-2172.2002

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  42 in total

1.  Cerulenin.

Authors:  S Omura
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

2.  The effect of pyrazinamide (aldinamide) on experimental tuberculosis in mice.

Authors:  L MALONE; A SCHURR; H LINDH; D McKENZIE; J S KISER; J H WILLIAMS
Journal:  Am Rev Tuberc       Date:  1952-05

3.  Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.

Authors:  O Zimhony; J S Cox; J T Welch; C Vilchèze; W R Jacobs
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

4.  Activity and penetration of antituberculosis drugs in mouse peritoneal macrophages infected with Mycobacterium microti OV254.

Authors:  J Dhillon; D A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

5.  Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis.

Authors:  R A Slayden; R E Lee; J W Armour; A M Cooper; I M Orme; P J Brennan; G S Besra
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

6.  Scanning electron microscopy of the H37Ra strain of Mycobacterium tuberculosis exposed to isoniazid.

Authors:  K Takayama; L Wang; R S Merkal
Journal:  Antimicrob Agents Chemother       Date:  1973-07       Impact factor: 5.191

7.  Intracellular fate of Mycobacterium avium: use of dual-label spectrofluorometry to investigate the influence of bacterial viability and opsonization on phagosomal pH and phagosome-lysosome interaction.

Authors:  Y K Oh; R M Straubinger
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

8.  Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic.

Authors:  A J Crowle; R Dahl; E Ross; M H May
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

9.  Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method.

Authors:  M Salfinger; L B Heifets
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

10.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.

Authors:  S T Cole; R Brosch; J Parkhill; T Garnier; C Churcher; D Harris; S V Gordon; K Eiglmeier; S Gas; C E Barry; F Tekaia; K Badcock; D Basham; D Brown; T Chillingworth; R Connor; R Davies; K Devlin; T Feltwell; S Gentles; N Hamlin; S Holroyd; T Hornsby; K Jagels; A Krogh; J McLean; S Moule; L Murphy; K Oliver; J Osborne; M A Quail; M A Rajandream; J Rogers; S Rutter; K Seeger; J Skelton; R Squares; S Squares; J E Sulston; K Taylor; S Whitehead; B G Barrell
Journal:  Nature       Date:  1998-06-11       Impact factor: 49.962

View more
  44 in total

1.  Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis.

Authors:  Wanliang Shi; Xuelian Zhang; Xin Jiang; Haiming Yuan; Jong Seok Lee; Clifton E Barry; Honghai Wang; Wenhong Zhang; Ying Zhang
Journal:  Science       Date:  2011-08-11       Impact factor: 47.728

2.  Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.

Authors:  Tawanda Gumbo; Chandima S W Siyambalapitiyage Dona; Claudia Meek; Richard Leff
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

3.  Pyrazinoic acid decreases the proton motive force, respiratory ATP synthesis activity, and cellular ATP levels.

Authors:  Ping Lu; Anna C Haagsma; Hoang Pham; Janneke J Maaskant; Selena Mol; Holger Lill; Dirk Bald
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

Review 4.  Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide.

Authors:  Pooja Gopal; Gerhard Grüber; Véronique Dartois; Thomas Dick
Journal:  Trends Pharmacol Sci       Date:  2019-11-06       Impact factor: 14.819

Review 5.  The Bewildering Antitubercular Action of Pyrazinamide.

Authors:  Elise A Lamont; Nicholas A Dillon; Anthony D Baughn
Journal:  Microbiol Mol Biol Rev       Date:  2020-03-04       Impact factor: 11.056

6.  Long-Chain Fatty Acyl Coenzyme A Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis.

Authors:  Brandon C Rosen; Nicholas A Dillon; Nicholas D Peterson; Yusuke Minato; Anthony D Baughn
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

7.  Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis.

Authors:  Pooja Gopal; Michelle Yee; Jickky Sarathy; Jian Liang Low; Jansy P Sarathy; Firat Kaya; Véronique Dartois; Martin Gengenbacher; Thomas Dick
Journal:  ACS Infect Dis       Date:  2016-08-08       Impact factor: 5.084

8.  Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis.

Authors:  Moses Njire; Na Wang; Bangxing Wang; Yaoju Tan; Xingshan Cai; Yanwen Liu; Julius Mugweru; Jintao Guo; H M Adnan Hameed; Shouyong Tan; Jianxiong Liu; Wing Wai Yew; Eric Nuermberger; Gyanu Lamichhane; Jinsong Liu; Tianyu Zhang
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

9.  Molecular epidemiological study of pyrazinamide-resistance in clinical isolates of mycobacterium tuberculosis from South India.

Authors:  Muthuraj Muthaiah; Sridharan Jagadeesan; Nisha Ayalusamy; Manupriya Sreenivasan; Sambamurthy Sangamesvara Prabhu; Usharani Muthuraj; Kamatchiyammal Senthilkumar; Saroja Veerappan
Journal:  Int J Mol Sci       Date:  2010-07-07       Impact factor: 5.923

10.  Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.

Authors:  Silvana C Ngo; Oren Zimhony; Woo Jin Chung; Halimah Sayahi; William R Jacobs; John T Welch
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.